Novel insights into neuronal activity-dependent gene expression by CREB
December 27, 2016
Neuronal activity mediates the formation of neuronal circuits in the cerebral cortex. These processes are regulated by the transcription factor CREB, which regulates gene expression in neuronal activity-dependent processes. Neuronal activity enhances CREB-mediated transcription but the mechanisms remain unclear.
Research reveals the importance of long non-coding RNA regulating cellular processes
December 26, 2016
Scientific research over the past decade has concentrated almost exclusively on the 2 percent of the genome's protein coding regions, virtually ignoring the other 98 percent, a vast universe of non-coding genetic material previously dismissed as nothing more than 'junk.' Now, a team led by investigators at Beth Israel Deaconess Medical Center (BIDMC) reveals that one type -- called long non-coding RNA (lncRNA) -- may be critically important for controlling cellular components in a tissue-specific manner. Published online today in the journal Nature, the new research points to an lncRNA's key role in helping control processes related to muscle regeneration and cancer.
Endometrial cancer mutations are detectable in uterine lavage fluid before a cancer is diagnosed
December 26, 2016
Mutations that have been linked to endometrial cancer can be found in the uterine lavage fluid of pre- and post-menopausal women both with and without detectable cancer, according to a study published in PLOS Medicine by John Martignetti, MD, PhD of the Icahn School of Medicine at Mount Sinai and colleagues.
SEBIO Investor & Partnering
September 12-15, 2012
We are delighted to be working with Merck, who is a leader in the rapidly developing immuno-oncology space.We believe our Retrocyte Display technology has significant advantages for creation of high quality antibody development candidates. This collaboration broadens our efforts in immuno-oncology beyond our previously disclosed checkpoint programs with a world-class research and development partner.
CED Tech Venture
December 3-6, 2011
Biothera’s Imprime PGG and Merck’s anti-PD-1 inhibitor KEYTRUDA® (pembrolizumab) to be evaluated in combination for patients with either advanced melanoma or metastatic triple negative breast cancer (TNBC).Under previous agreement, Big Ten Cancer Research Consortium (BTCRC) plans to initiate a Phase 1b/2 Imprime PGG/KEYTRUDA trial in patients with non-small cell lung cancer (NSCLC).
CNS Diseases World
October 11-13, 2010
The Blavatnik Biomedical Accelerator, supports the University’s innovative, early-stage life science research to promote the successful development of important biomedical advances that will improve health care and benefit society.The Blavatnik Biomedical Accelerator at Harvard University bridges the gap between the innovative life science research at Harvard and the successful development of high-impact biomedical products.
